10: How the MDR has changed the roles and responsibilities of “economic operators”
PharmaLex Talks8 Elo 2022

10: How the MDR has changed the roles and responsibilities of “economic operators”

Under the Medical Devices Regulation economic operators – that is manufacturers, the authorised representative, importers and distributors – all face new roles and obligations. While some of these responsibilities existed under the Medical Devices Directive, workload will be impacted. From requirements around Eudamed, to having a person responsible for regulatory compliance, to ensuring certain obligations are properly followed through to complaint management, the roles of all economic operators are affected and require careful consideration by companies with devices in the European market.

Clare Huntington is Director and Head of Medical Devices / IVD UK at PharmaLex

Clare leads the UK and EU teams and consults on industry-wide issues including drug/device combination products, clinical trials, device classification and regulatory submissions, and post-market requirements. Clare has worked in a variety of roles in the medical device space during her career, including the MHRA, a Clinical Research Organisation, as an EU Authorised Representative, as well as industry, leading the regulatory affairs activities. This has given her a broad understanding of the EU regulatory landscape which enables her to provide comprehensive advice to clients that covers the full product life-cycle.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(37)

37: Optimizing revenue from mature products

37: Optimizing revenue from mature products

We talk with Paula King, Director, Regulatory Affairs at PharmaLex to better understand the growing trend toward regulatory outsourcing, particularly of the mature product portfolio. Hear how leading ...

18 Heinä 20259min

36: What’s happening with eCTD 4.0: New and future developments

36: What’s happening with eCTD 4.0: New and future developments

Join Karl-Heinz Loebel, Director, Regulatory Informatics & Operations at PharmaLex, as he discusses current progress of eCTD 4.0. Ten years after the eCTD 4.0 standard became available for submissions...

18 Heinä 202520min

35: Challenges and best practices for managing local pharmacovigilance activities

35: Challenges and best practices for managing local pharmacovigilance activities

In this episode of the PharmaLex Talks Podcast, sits down with Alex Brenchat, Vice President of Local Affiliate Pharmacovigilance Services at PharmaLex, a Cencora company. Together, they explore the c...

9 Touko 202512min

34: Environmental Risk Assessment and its growing importance in the German Pharma Strategy

34: Environmental Risk Assessment and its growing importance in the German Pharma Strategy

Join Angela-Vogt Eisele, Associate Director Scientific Affairs at PharmaLex, a Cencora company for this podcast, where she shares her expertise in Environmental Risk Assessment and its growing importa...

14 Huhti 202520min

33: Finding the best approach to manage sterility assurance

33: Finding the best approach to manage sterility assurance

Join PharmaLex's Patrick Nieuwenhuizen for this podcast, where he shares his expertise in sterility assurance and how manufacturers can demonstrate that the finished product is sterile through a holis...

27 Tammi 202515min

32: Commercialization Readiness

32: Commercialization Readiness

Pharmaceutical companies new to the EU market must navigate complex and varying commercialization requirements. The podcast highlights key steps for commercialization readiness in Europe, focusing on ...

4 Marras 202413min

31: Key Steps for Site Inspection Readiness

31: Key Steps for Site Inspection Readiness

Louise Uí Fhatharta bio Quality professional with over 20 years’ experience in Microbiology, Quality Control and Quality Assurance roles in the Pharmaceutical Industry including Sterile Fill Finish a...

27 Kesä 202417min

30: CSS Overview

30: CSS Overview

A contamination control strategy (CCS) is integral to Annex 1 and is fundamentally about patient safety and identifying and avoiding contamination pathways. Manufacturers are expected to implement a C...

9 Touko 202414min

Suosittua kategoriassa Politiikka ja uutiset

uutiscast
aikalisa
politiikan-puskaradio
rss-ootsa-kuullut-tasta
ootsa-kuullut-tasta-2
rss-vaalirankkurit-podcast
tervo-halme
otetaan-yhdet
rss-podme-livebox
viisupodi
et-sa-noin-voi-sanoo-esittaa
rss-pinnalla
rss-asiastudio
rss-girls-finish-f1rst
linda-maria
rss-raha-talous-ja-politiikka
rss-ulkopoditiikkaa
rikosmyytit
the-ulkopolitist
rss-polikulaari-pitka-kiekko-ja-muut-ts-podcastit